Psychopharmacology

, Volume 110, Issue 1–2, pp 119–124 | Cite as

Clozapine's functional mesolimbic selectivity is not duplicated by the addition of anticholinergic action to haloperidol: a brain stimulation study in the rat

  • Eliot L. Gardner
  • Leslie Stern Walker
  • William Paredes
Original Investigations

Abstract

This study examined whether the anticholinergic potency of the clinically superior antipsychotic drug clozapine contributes to clozapine's anatomically-selective functional inhibition of the mesolimbic dopamine (DA) system, using an electrical brain-stimulation reward (BSR) paradigm in rats that has been previously shown to be highly sensitive to clozapine's mesolimbic functional selectivity. Rats were chronically administered saline, clozapine, haloperidol, or haloperidol plus the anticholinergic compound trihexyphenidyl, and threshold sensitivity of the mesolimbic and nigrostriatal DA systems was assessed using the BSR paradigm, to infer degree of functional DA blockade produced by the chronic drug regimens. Chronic saline produced no change in either DA system. Congruent with previous findings, chronic clozapine powerfully inhibited the mesolimbic DA system but spared the nigrostriatal DA system. Also congruent with previous findings, chronic haloperidol powerfully inhibited both DA systems. Compared to chronic haloperidol alone, chronic haloperidol plus chronic trihexyphenidyl exerted diminished anti-DA action in both the mesolimbic and nigrostriatal DA systems. These results suggest that clozapine's anticholinergic potency is not an adequate explanation for its functional mesolimbic selectivity.

Key words

Clozapine Haloperidol Trihexyphenidyl Dopamine Acetylcholine Mesolimbic Nigrostriatal Antipsychotic Neuroleptic Atypical Schizophrenia Psychosis Substantia nigra Ventral tegmental area Brain stimulation reward Self-stimulation ICSS 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Baldessarini RJ (1985) Chemotherapy in psychiatry: principles and practice, 2nd edn. Harvard University Press, CambridgeGoogle Scholar
  2. Baldessarini RJ, Tarsy D (1979) Relationship of the actions of neuroleptic drugs to the pathophysiology of tardive dyskinesia. Int Rev Neurobiol 21:1–45Google Scholar
  3. Blaha CD, Lane RF (1987) Chronic treatment with classical and atypical antipsychotic drugs differentially decreases dopamine release in striatum and nucleus accumbens in vivo. Neurosci Lett 78:199–204Google Scholar
  4. Bolden C, Cusack B, Richelson E (1992) Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J Pharmacol Exp Ther 260:576–580Google Scholar
  5. Casey DE (1989) Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 99[suppl]:S47-S53Google Scholar
  6. Chen J, Paredes W, Gardner EL (1991) Chronic treatment with clozapine selectively decreases basal dopamine release in nucleus accumbens but not in caudate-putamen as measured by in vivo brain microdialysis: further evidence for depolarization block. Neurosci Lett 122:127–131Google Scholar
  7. Chen J, Ruan D, Paredes W, Gardner EL (1992a) Effects of acute and chronic clozapine on dopaminergic function in medial prefrontal cortex of awake, freely moving rats. Brain Res 571:235–241Google Scholar
  8. Chen J, Paredes W, van Praag HM, Gardner EL (1992b) Serotonin denervation enhances responsiveness of presynaptic dopamine efflux to acute clozapine in nucleus accumbens but not in caudate-putamen. Brain Res 582:173–179Google Scholar
  9. Chiodo LA, Bunney SB (1983) Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 3:1607–1619Google Scholar
  10. Chiodo LA, Bunney SB (1985) Possible mechanisms by which repeated clozapine administration differentially affects the activity of two subpopulations of midbrain dopamine neurons. J Neurosci 5:2539–2544Google Scholar
  11. Coward DM, Imperato A, Urwyler S, White TG (1989) Biochemical and behavioural properties of clozapine. Psychopharmacology 99[suppl]:S6-S12Google Scholar
  12. Creese I (1983) Classical and atypical antipsychotic drugs: new insights. TINS 6:479–481Google Scholar
  13. De Simoni MG, Dal Toso G, Fodritto F, Sokola A, Algeri S (1987) Modulation of striatal dopamine metabolism by the activity of dorsal raphe serotonergic afferences. Brain Res 411:81–88Google Scholar
  14. Ettenberg A, Milner PM (1977) Effects of dopamine supersensitivity on lateral hypothalamic self-stimulation in rats. Pharmacol Biochem Behav 7:507–514Google Scholar
  15. Farde L, Wiesel FA, Nordström A-L, Sedvall G (1989) D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology 99[suppl]:S28-S31Google Scholar
  16. Fischette CT, Nock B, Renner K (1987) Effects of 5,7-dihydroxytryptamine on serotonin1 and serotonin2 receptors throughout the rat central nervous system using quantitative autoradiography. Brain Res 421:263–279Google Scholar
  17. Gardner EL (1992a) Neuroanatomical specificity of action of the atypical antipsychotics: implications for a new era in the pharmacotherapy of schizophrenia. In: Lindenmayer J-P, Kay SR (eds) New biological vistas on schizophrenia. Bruner/Mazel, New YorkGoogle Scholar
  18. Gardner EL (1992b) Brain reward mechanisms. In: Lowinson JH, Ruiz P, Millman RB (eds) Substance abuse: a comprehensive textbook, 2nd edn. Williams & Wilkins, BaltimoreGoogle Scholar
  19. Gardner EL, Seeger TF (1988) Anatomically selective action of atypical neuroleptics on the mesocorticolimbic dopamine system. Ann NY Acad Sci 537:502–504Google Scholar
  20. Gardner EL, Paredes W, Smith D, Donner A, Milling C, Cohen D, Morrison D (1988) Facilitation of brain stimulation reward by Δ9-tetrahydrocannabinol. Psychopharmacology 96:142–144Google Scholar
  21. Gerlach J (1991) New antipsychotics: classification, efficacy, and adverse effects. Schizophr Bull 17:289–309Google Scholar
  22. Hand TH, Hu X-T, Wang RY (1987) Differential effects of acute clozapine and haloperidol on the activity of ventral tegmental (A10) and nigrostriatal (A9) dopamine neurons. Brain Res 415:257–269Google Scholar
  23. Heal DJ, Green AR, Bullin DJ, Grahame-Smith DG (1976) Single and repeated administration of neuroleptic drugs to rats: effects on striatal dopamine-sensitive adenylate cyclase and locomotor activity. Psychopharmacology 49:287–300Google Scholar
  24. Hetey L, Drescher K (1986) Influence of antipsychotics on presynaptic receptors modulating the release of dopamine in synaptosomes of the nucleus accumbens of rats. Neuropharmacology 25:1103–1109Google Scholar
  25. Huff RM, Adams RN (1980) Dopamine release in n. accumbens and striatum by clozapine: simultaneous monitoring by in vivo electrochemistry. Neuropharmacology 19:587–590Google Scholar
  26. Jann MW (1991) Clozapine. Pharmacotherapy 11:179–195Google Scholar
  27. Johnstone EC, Crow TJ, Ferrier IN, Firth CD, Owens DGC, Bourne RC, Gamble SJ (1983) Adverse effects of anticholinergic medication on positive schizophrenic symptoms. Psychol Med 13:513–527Google Scholar
  28. Kane J (1992) Atypical neuroleptics in the treatment of schizophrenia. In: Lindenmayer J-P, Kay SR (eds) New biological vistas on schizophrenia. Bruner/Mazel, New YorkGoogle Scholar
  29. Kane J, Honigfeld G, Singer J, Meltzer H, et al. (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789–796Google Scholar
  30. Kirk RE (1982) Experimental design, 2nd edn. Brooks/Cole, Monterey, CAGoogle Scholar
  31. Klawans HL (1973) The pharmacology of tardive dyskinesias. Am J Psychiatry 130:82–86Google Scholar
  32. Lane RF, Blaha CD (1986) Electrochemistry in vivo: application to CNS pharmacology. Ann NY Acad Sci 473:50–69Google Scholar
  33. Meltzer HY, Bastani B, Ramirez L, Matsubara S (1989a) Clozapine: new research on efficacy and mechanism of action. Eur Arch Psychiatr Neurol Sci 238:332–339Google Scholar
  34. Meltzer HY, Matsubara S, Lee JC (1989b) The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 25:390–392Google Scholar
  35. Mitchelson F (1988) Muscarinic receptor differentiation. Pharmacol Ther 37:357–423Google Scholar
  36. Pazos A, Palacios JM (1985) Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors. Brain Res 346:205–230Google Scholar
  37. Pellegrino LJ, Pellegrino AS, Cushman AJ (1979) A stereotaxic atlas of the rat brain. Plenum Press, New YorkGoogle Scholar
  38. Sayers AC, Bürki HR, Ruch W, Asper H (1976) Anticholinergic properties of antipsychotic drugs and their relation to extrapyramidal side-effects. Psychopharmacology 51:15–22Google Scholar
  39. Seeger TF, Gardner EL (1979) Enhancement of self-stimulation behavior in rats and monkeys after chronic neuroleptic treatment: evidence for mesolimbic supersensitivity. Brain Res 175:49–57Google Scholar
  40. Seeger TF, Gardner EL, Bridger WF (1981) Increase in mesolimbic electrical self-stimulation after chronic haloperidol: reversal byl-dopa or lithium. Brain Res 215:404–409Google Scholar
  41. Seeman P (1987) Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1:133–152Google Scholar
  42. Singh MM, Kay SR (1979) Therapeutic antagonism between anticholinergic anti-Parkinsonian agents and neuroleptics in schizophrenia: implications for a neuropharmacological model. Neuropsychobiology 5:74–86Google Scholar
  43. Stevens RC (1979) Schizophrenia and dopamine dysregulation in the mesolimbic system. TINS 2:102–105Google Scholar
  44. Ungerstedt U (1971) Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigrostriatal dopamine system. Acta Physiol Scand 82[suppl 367]:69–93Google Scholar
  45. van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, Civelli O (1991) Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350:610–614Google Scholar
  46. Waeber C, Dixon K, Hoyer D, Palacios JM (1988) Localisation by autoradiography of neuronal 5-HT3 receptors in the mouse CNS. Eur J Pharmacol 151:351–352Google Scholar
  47. White FJ, Wang RY (1983) Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 221:1054–1057Google Scholar
  48. Wise RA, Rompre P-P (1989) Brain dopamine and reward. Annu Rev Psychol 40:191–225Google Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • Eliot L. Gardner
    • 1
    • 2
  • Leslie Stern Walker
    • 1
  • William Paredes
    • 1
  1. 1.Program in Brain and Behavior, Department of PsychiatryAlbert Einstein College of MedicineBronxUSA
  2. 2.Department of NeuroscienceAlbert Einstein College of MedicineBronxUSA

Personalised recommendations